<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Pulmonary hypertension in patients with end-stage kidney disease
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Pulmonary hypertension in patients with end-stage kidney disease
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Pulmonary hypertension in patients with end-stage kidney disease
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            William Hopkins, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Thomas A Golper, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Gerald A Beathard, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeffrey S Berns, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Ellen D Dillavou, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Eric N Taylor, MD, MSc, FASN
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kathryn A Collins, MD, PhD, FACS
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Geraldine Finlay, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jul 21, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H111099120">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pulmonary hypertension (PH) in patients with end-stage kidney disease (ESKD) is a serious condition that is associated with an increased risk of cardiovascular events and death [
         <a href="#rid1">
          1-6
         </a>
         ]. Identifying PH can be challenging but is important in this population since management strategies differ from those for patients with ESKD who do not have PH.
        </p>
        <p>
         The presentation, diagnosis, and management of patients with ESKD and PH is presented in this topic review. The evaluation and management of PH in other populations are discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/8249.html" rel="external">
          "Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/121912.html" rel="external">
          "Treatment and prognosis of pulmonary arterial hypertension in adults (group 1)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/112486.html" rel="external">
          "Pulmonary hypertension due to left heart disease (group 2 pulmonary hypertension) in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/8258.html" rel="external">
          "Pulmonary hypertension due to lung disease and/or hypoxemia (group 3 pulmonary hypertension): Treatment and prognosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/16637.html" rel="external">
          "Chronic thromboembolic pulmonary hypertension: Initial management and evaluation for pulmonary artery thromboendarterectomy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3715598996">
         <span class="h1">
          DEFINITION
         </span>
         <span class="headingEndMark">
          —
         </span>
         PH is a chronic progressive disease characterized by an elevated pulmonary arterial pressure. While there is no specific hemodynamic cutoff used to define PH in patients with ESKD, we typically consider a mean pulmonary arterial pressure (mPAP) greater than 20 mmHg at rest as elevated [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2078941479">
         <span class="h1">
          INCIDENCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         The true incidence of PH in patients with ESKD is unknown since most studies report incidence rates based upon echocardiographic data and variable criteria. Nonetheless, rates of PH appear to be higher in patients with ESKD compared with the general population (approximately 10 percent in the latter) and vary depending upon the stage of kidney disease and type and vintage of dialysis.
        </p>
        <p>
         As examples, rates have been cited as the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with stage 5 chronic kidney disease (CKD) – 9 to 39 percent [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients undergoing hemodialysis – 19 to 69 percent [
         <a href="#rid9">
          9,10
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients undergoing peritoneal dialysis – 13 to 19 percent [
         <a href="#rid8">
          8,11-13
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         PH rates rise as kidney failure progresses and may increase over time for those on dialysis. In one study, rates of PH in patients with nondialysis CKD rose with disease stage (stage 3 [22 percent], stage 4 [24 percent], and stage 5 [32 percent]) [
         <a href="#rid14">
          14
         </a>
         ]. Another retrospective study reported an increasing incidence of PH over time among those on dialysis (dialysis &lt;1 year [25 percent], dialysis 1 to 2 years [38 percent], and dialysis &gt;2 years [58 percent]) [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
         Incidence rates may be lower than those reported in echocardiographic studies when the diagnostic gold standard, right heart catheterization (RHC), is used to detect PH.
        </p>
        <p>
         In one study, among 31 patients undergoing hemodialysis, RHC identified PH in 78 percent, the majority of whom had postcapillary PH (65 percent; ie, PH associated with increased left-sided cardiac filling pressures, group 2 PH) and a minority of whom had precapillary PH (13 percent; ie, group 1 pulmonary arterial hypertension)  (
         <a class="graphic graphic_table graphicRef105764" href="/z/d/graphic/105764.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid16">
          16
         </a>
         ]. Among 31 patients who had
         <strong>
          not
         </strong>
         yet started hemodialysis, postcapillary PH was diagnosed in 71 percent, and precapillary PH was detected in 6 percent. The prevalence of precapillary PH may be higher than would be expected in the general population [
         <a href="#rid17">
          17-19
         </a>
         ].
        </p>
        <p>
         No sex or racial predilection for PH in patients with ESKD has been described.
        </p>
        <p class="headingAnchor" id="H1666431873">
         <span class="h1">
          CLASSIFICATION AND PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         A five-group classification system categorizes PH based on similar pathophysiologic mechanisms, hemodynamic characteristics, and therapeutic management  (
         <a class="graphic graphic_table graphicRef66348" href="/z/d/graphic/66348.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid7">
          7
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Group 1 – Pulmonary artery hypertension (PAH)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Group 2 – PH due to left heart disease
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Group 3 – PH due to lung diseases and/or hypoxia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Group 4 – PH due to pulmonary artery obstructions (eg, chronic thromboembolic disease)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Group 5 – PH with unclear and/or multifactorial mechanisms
        </p>
        <p>
        </p>
        <p>
         The term PAH is used for group 1 disease while PH is used for all others. PH that occurs in patients with ESKD is typically classified as group 5 PH  (
         <a class="graphic graphic_table graphicRef120362" href="/z/d/graphic/120362.html" rel="external">
          table 3
         </a>
         ) since there is no single unifying mechanism that explains the pathogenesis of PH in this population. However, some patients may be partially or completely classified into another group, provided they meet select criteria for that group. Further details on classification are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/8249.html" rel="external">
          "Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Postdiagnostic testing and classification'
         </a>
         .)
        </p>
        <p>
         As a multifactorial disorder, several pathogenetic factors have been implicated in the development of PH in patients with ESKD. These include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          High prevalence of comorbidities associated with PH
         </strong>
         – In patients with ESKD, there is a high prevalence of comorbidities, particularly cardiac disease, that potentially contribute to the higher than usual prevalence of PH in this population. However, their contribution to and pathogenetic role in the development of actual PH are unclear. As examples:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         There is a high prevalence of heart failure among patients with ESKD (30 to 77 percent) [
         <a href="#rid20">
          20-25
         </a>
         ] and consequently a high incidence of group 2 PH [
         <a href="#rid16">
          16
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1846.html" rel="external">
          "Overview of screening and diagnosis of heart disease in patients on dialysis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with connective tissue disease (CTD) may have both CTD-PAH and chronic kidney disease (CKD) [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Pulmonary and sleep disorders often coexist with CKD (ranging from 17 to 53 percent of patients with ESKD) [
         <a href="#rid27">
          27-35
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16197.html" rel="external">
          "Sleep disorders in end-stage kidney disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         There is an increased prevalence of thromboembolic disease in patients with ESKD [
         <a href="#rid36">
          36-38
         </a>
         ] although recurrent embolization from repeated arteriovenous (AV) access thrombectomies does not appear to be a risk factor for the development of PH in this population [
         <a href="#rid37">
          37-39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Role of arteriovenous (AV) access flow
         </strong>
         – AV access flow has been implicated as a
         <strong>
          contributing
         </strong>
         factor to the development of PH in patients with ESKD on dialysis. However, it is unlikely that AV access is a stand-alone factor for the development of PH.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The role of AV access flow in the development of PH is considered most likely due to increased vascular flow in the setting of altered cardiovascular physiology or pathology, and hormonal and metabolic alterations of ESKD. As an example, the increase in cardiac output following access creation is accompanied by an increase in pulmonary arterial pressure [
         <a href="#rid1">
          1,40-44
         </a>
         ]. The change directly correlates with the blood flow through the AV access [
         <a href="#rid2">
          2,45-47
         </a>
         ] and can be attenuated or resolve in some patients by AV access compression or closure [
         <a href="#rid2">
          2,12,41,48,49
         </a>
         ]. Increased AV flow over time during dialysis may also contribute to the increased risk of developing PH while on dialysis [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fluid overload
         </strong>
         – Fluid overload has been implicated in the development of ESKD-related PH (ESKD-PH). Evidence to support this theory includes the observation that PH may improve following ultrafiltration [
         <a href="#rid50">
          50
         </a>
         ] or successful kidney transplantation [
         <a href="#rid51">
          51
         </a>
         ] (usually by improving cardiac function) and the known effects of chronic increased flow through the pulmonary vascular bed in the development of pulmonary arterial hypertension. (See
         <a class="medical medical_review" href="/z/d/html/8247.html" rel="external">
          "The epidemiology and pathogenesis of pulmonary arterial hypertension (Group 1)", section on 'General physiologic mechanisms'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Endothelial dysfunction
         </strong>
         – Endothelial dysfunction in patents with ESKD has also been implicated in the development of PH [
         <a href="#rid52">
          52-57
         </a>
         ]. Endothelial dysfunction leads to an impaired capacity of the endothelium to regulate vascular tone mediated by nitric oxide (NO). Reduced levels of NO have been reported in patients on hemodialysis with PH compared with those without PH, and hemodialysis treatment results in greater posttreatment elevations of NO in those without versus with PH [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The major contributor to reduced levels of NO in CKD is asymmetric dimethylarginine (ADMA), an endogenous inhibitor of NO synthase [
         <a href="#rid59">
          59
         </a>
         ]. This compound accumulates in CKD and negatively correlates with glomerular filtration rate (GFR) [
         <a href="#rid60">
          60-62
         </a>
         ]. ADMA levels are elevated in patients with early phases of kidney disease, even before GFR is significantly reduced [
         <a href="#rid63">
          63
         </a>
         ]. Both ADMA and the vasoconstrictor endothelin-1 have been shown to be significantly elevated in patients with predialysis ESKD [
         <a href="#rid15">
          15,64
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Miscellaneous
         </strong>
         – Other factors that have been cited as possibly playing a role in the development of PH in patients with ESKD include the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Pulmonary vascular calcification [
         <a href="#rid65">
          65,66
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7222.html" rel="external">
          "Vascular calcification in chronic kidney disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Neutrophil activation related to exposure to bioincompatible dialysis membranes [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1478502799">
         <span class="h1">
          CLINICAL FEATURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The symptoms and signs of PH in patients with ESKD are the same as in those without ESKD (eg, progressive dyspnea, fatigue, syncope, signs of right heart failure). Similar to PH associated with other etiologies, PH in patients with ESKD is progressive and may only be suspected when PH progresses in severity and right heart failure develops. Further details regarding the clinical presentation of PH are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/8249.html" rel="external">
          "Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1861623073">
         <span class="h1">
          DIAGNOSIS AND EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with ESKD and suspected PH should be co-evaluated by experts in nephrology and PH.
        </p>
        <p class="headingAnchor" id="H3429600741">
         <span class="h2">
          When to suspect PH in ESKD
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with end-stage kidney disease (ESKD), we maintain a high index of suspicion for pulmonary hypertension (PH) since the symptoms of volume overload (eg, dyspnea, edema, elevated jugular venous pressure) overlap with those of PH.
        </p>
        <p>
         Useful clues that may suggest PH in patients with ESKD include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Symptoms of heart failure that are resistant to maximal medical management.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A tricuspid insufficiency murmur in the absence of a cardiac rhythm device with transvenous leads [
         <a href="#rid17">
          17,67
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Electrocardiographic and/or echocardiographic evidence of right ventricular hypertrophy [
         <a href="#rid17">
          17
         </a>
         ], although a normal electrocardiogram or echocardiography does not exclude PH.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Worsening symptoms within days to weeks following arteriovenous (AV) access placement.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Poor tolerance of ultrafiltration in patients with dyspnea and hypervolemia.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3747593179">
         <span class="h2">
          Initial diagnostic evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Evaluation and diagnosis of PH in patients with ESKD are similar to those for patients without ESKD  (
         <a class="graphic graphic_algorithm graphicRef138556" href="/z/d/graphic/138556.html" rel="external">
          algorithm 1
         </a>
         ). We typically begin with transthoracic echocardiography (TTE), a search for common etiologies associated with PH, and the selective performance of right heart catheterization (RHC) to confirm or exclude PH. This evaluation is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8249.html" rel="external">
          "Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Initial diagnostic evaluation (noninvasive testing)'
         </a>
         .)
        </p>
        <p>
         In our experience, RHC is often needed in this population since RHC can distinguish precapillary from postcapillary disease  (
         <a class="graphic graphic_table graphicRef105764" href="/z/d/graphic/105764.html" rel="external">
          table 1
         </a>
         ), differentiate high-output from low-output heart failure, and determine whether PH is multifactorial in nature. In addition, RHC may provide therapeutic information in patients with an AV access when the response to manual compression is needed. Importantly, hemodynamic and other forms of testing should ideally be performed in the euvolemic state based upon an accurate assessment of the patient's dry weight. (See
         <a class="medical medical_review" href="/z/d/html/8249.html" rel="external">
          "Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Right heart catheterization'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H758021714">
         <span class="h2">
          Establishing the diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of ESKD-PH is ideally made based on RHC that demonstrates an elevated mean pulmonary artery pressure &gt;20mmHg. (See
         <a class="medical medical_review" href="/z/d/html/8249.html" rel="external">
          "Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
         However, in some patients, the diagnosis of PH is made clinically, using a constellation of findings and noninvasive testing, typically echocardiography (eg, patients with mild symptoms who clearly have group 2 or 3 PH). (See
         <a class="medical medical_review" href="/z/d/html/8249.html" rel="external">
          "Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Diagnosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8249.html" rel="external">
          "Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Group 2: PH due to left heart disease'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8249.html" rel="external">
          "Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Group 3: PH due to chronic lung disease and/or hypoxemia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4244580663">
         <span class="h2">
          Classification and assessment of arteriovenous access contribution
         </span>
         <span class="headingEndMark">
          —
         </span>
         The postdiagnostic evaluation with ESKD-PH involves appropriately classifying the patient  (
         <a class="graphic graphic_table graphicRef66348" href="/z/d/graphic/66348.html" rel="external">
          table 2
         </a>
         ) by assessing the potential contribution of existing comorbidities and/or precapillary disease to PH.
        </p>
        <p>
         Allocation of classification is important since, in general, only patients with pulmonary arterial hypertension (PAH; ie, group 1) are eligible for PAH-specific therapies (eg, pulmonary vasodilators) outside of the research trial setting. Assigning a classification generally involves evaluating available data, performing additional testing if needed, and obtaining the opinion of both the PH and nephrology expert. As an example, a patient with mild (CKD) due to scleroderma and no arteriovenous (AV) access who has classic findings of precapillary disease on RHC may be appropriately allocated into group 1 and may qualify for PAH-specific therapies. By contrast, a patient with ESKD who has components of both precapillary and postcapillary disease and who has known cardiopulmonary disease may be more appropriately classified as group 5 (ie, multifactorial and is not likely to qualify for PAH-specific therapy outside of a research setting). Further details regarding the diagnosis of PH and postdiagnostic testing for appropriate classification are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/8249.html" rel="external">
          "Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
         Additional postdiagnostic evaluation in select patients with ESKD who are on hemodialysis, involves assessing the relationship of AV access flow to PH (eg, patients with mild to moderate symptoms who are being evaluated for a flow reduction procedure). This can be determined by measuring pulmonary pressures before and after manually compressing the AV access. This maneuver may help predict whether banding/plication of the AV access may improve PH.
        </p>
        <p>
         In our clinical experience, the contribution of AV flow to PH can be assessed by manually compressing the AV access under therapeutic heparinization and a tourniquet set to at least 30 mmHg above systolic blood pressure for one minute while measuring pulmonary hemodynamics on RHC. If a significant component of the patient's PH is related to the AV access, pulmonary hemodynamic measurements should fall significantly [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8249.html" rel="external">
          "Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Right heart catheterization'
         </a>
         .)
        </p>
        <p>
         However, the definition of what constitutes a significant decrease is not established and is highly subjective. We consider a significant decrease as a reduction by at least 20 percent or more or normalization of the mean pulmonary artery pressure and right atrial pressure (and possibly the pulmonary capillary wedge pressure and left ventricular end-diastolic pressure) when the AV access is compressed [
         <a href="#rid2">
          2,68
         </a>
         ].
        </p>
        <p>
         While there is concern that compression of an AV access could lead to thrombosis (particularly if the access is an AV graft), in practice, this complication is rare, especially if the patient is systemically heparinized prior to AV access compression. Management of the thrombosed AV access is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/1971.html" rel="external">
          "Hemodialysis arteriovenous graft dysfunction and failure", section on 'Treatment of thrombosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1957.html" rel="external">
          "Failure of the mature hemodialysis arteriovenous fistula", section on 'Thrombosed fistula'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1382976197">
         <span class="h2">
          Differential diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with symptoms in whom PH is suspected, the differential diagnosis includes a wide spectrum of cardiopulmonary and other disorders, most of which are distinguished by routine investigations performed for PH. Further details regarding this differential are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/1436.html" rel="external">
          "Approach to the patient with dyspnea"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8249.html" rel="external">
          "Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Initial differential diagnosis'
         </a>
         .)
        </p>
        <p>
         The differential diagnosis of dyspnea and intradialytic hemodynamic instability includes heart failure and ischemic heart disease, which can be distinguished by TTE or stress testing. (See
         <a class="medical medical_review" href="/z/d/html/1945.html" rel="external">
          "Intradialytic hypotension in an otherwise stable patient", section on 'Second-line approach'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3689996749">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with ESKD-PH, we follow the same basic principles of management as for other patients with PH. Patients should be comanaged by clinicians who have expertise in ESKD as well as clinicians with expertise in PH. (See
         <a class="medical medical_review" href="/z/d/html/121912.html" rel="external">
          "Treatment and prognosis of pulmonary arterial hypertension in adults (group 1)"
         </a>
         .)
        </p>
        <p>
         The major focus of management involves the following  (
         <a class="graphic graphic_algorithm graphicRef138519" href="/z/d/graphic/138519.html" rel="external">
          algorithm 2
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reducing volume overload and left-sided heart pressures (since a sizeable proportion of patients with ESKD-PH have left ventricular systolic and/or diastolic dysfunction that contributes to PH). (See
         <a class="local">
          'General measures in all patients'
         </a>
         below and
         <a class="local">
          'Volume management'
         </a>
         below and
         <a class="local">
          'Classification and pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Planning a dialysis modality for those with PH who are not yet on dialysis. (See
         <a class="local">
          'Predialysis patients'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Managing dialysis access and therapy for those who are diagnosed while on dialysis. (See
         <a class="local">
          'Patients on hemodialysis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Regardless of dialysis modality and access, patients with ESKD-PH, particularly those with arteriovenous (AV) access, need close monitoring for deterioration of PH. (See
         <a class="local">
          'Monitoring for PH'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1479113775">
         <span class="h2">
          General measures in all patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         These include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Routine pulmonary and PH care
         </strong>
         – Patients with ESKD-PH should exercise as tolerated, receive routine vaccinations  (
         <a class="graphic graphic_figure graphicRef62130" href="/z/d/graphic/62130.html" rel="external">
          figure 1
         </a>
         ), be counselled against smoking and vaping, and maintain a normal body mass index. When indicated, they should also be treated with oxygen and diuretics (when feasible).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We do
         <strong>
          not
         </strong>
         typically anticoagulate this population unless another indication is present (eg, atrial fibrillation).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Females of childbearing age should be counselled regarding the risks of pregnancy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Such general measures are similar to those in patients with PH and are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/121912.html" rel="external">
          "Treatment and prognosis of pulmonary arterial hypertension in adults (group 1)", section on 'General measures and supportive therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Routine kidney disease care
         </strong>
         – Other routine aspects of kidney disease care, including management of systemic hypertension, anemia, and chronic kidney disease (CKD)-mineral and bone disorder, may take on even more importance for prevention and management of PH, but there is no evidence to guide specific management alterations in PH. (See
         <a class="medical medical_review" href="/z/d/html/7172.html" rel="external">
          "Overview of the management of chronic kidney disease in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We typically manage volume aggressively. The principles of dialysis management are discussed below. (See
         <a class="local">
          'Volume management'
         </a>
         below and
         <a class="local">
          'Patients on peritoneal dialysis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Optimizing therapy for comorbidities
         </strong>
         – We optimize therapies for any comorbidities known to be associated with or worsen PH, particularly heart failure, obstructive sleep apnea, and underlying lung disease, all of which are common in patients with ESKD. Volume management is particularly important in those with group 2 PH and group 5 PH  (
         <a class="graphic graphic_table graphicRef66348" href="/z/d/graphic/66348.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/121085.html" rel="external">
          "Overview of the management of heart failure with reduced ejection fraction in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7695.html" rel="external">
          "Obstructive sleep apnea: Overview of management in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/112486.html" rel="external">
          "Pulmonary hypertension due to left heart disease (group 2 pulmonary hypertension) in adults", section on 'Optimized management of left heart disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1557357817">
         <span class="h2">
          Dialysis management
         </span>
         <span class="headingEndMark">
          —
         </span>
         The approach to dialysis management in patients with ESKD depends upon whether the patient is predialysis or already receiving dialysis. Because AV access flow can impact cardiopulmonary hemodynamics, access flow volume must be a consideration in dialysis access planning and management. Access flow monitoring and measurement are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/1970.html" rel="external">
          "Clinical monitoring and surveillance of the mature hemodialysis arteriovenous fistula", section on 'Intra-access flow rate'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1965.html" rel="external">
          "Clinical monitoring and surveillance of hemodialysis arteriovenous grafts to prevent thrombosis", section on 'Intra-access blood flow monitoring'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15074.html" rel="external">
          "High-flow hemodialysis arteriovenous access", section on 'Access flow measurement'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2043173410">
         <span class="h3">
          Predialysis patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Because high flow through an AV access can contribute to the development of PH in patients with ESKD, we evaluate predialysis patients for the presence of PH as part of dialysis access planning. The presence of PH should influence the selection of dialysis modality and, for those who will undergo hemodialysis access selection. The recommended approach for the patient is as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with preexisting PH who are being considered for maintenance dialysis, we suggest peritoneal dialysis (PD) rather than hemodialysis (HD) as the choice of dialysis modality. This preference is clear for patients who are symptomatic; however, no evidence-based criteria are available to guide planning in patients with asymptomatic PH who are being considered for dialysis such that clinical judgment is necessary for the latter. Factors that weigh into the decision to perform PD are complex and are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1858.html" rel="external">
          "Evaluating patients for chronic peritoneal dialysis and selection of modality", section on 'Available modalities'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Our preference for PD is based upon the rationale that PD obviates the need for AV access, thereby eliminating increases in blood flow that could worsen PH. In addition, PD provides daily ultrafiltration that may prevent interdialytic volume overload that can be seen with HD.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For most patients with PH who are not suited to, decline, or fail PD, we evaluate for HD. We prefer using a low-flow AV access (such as a radial-cephalic AV fistula) for HD as this option may be sufficient to provide adequate flow for effective dialysis while limiting the impact of AV flow on worsening PH. This must be balanced, however, against the likelihood that a low-flow AV access may not have sufficient flow for hemodialysis. However, if the patient has a limited life expectancy (ie, months), we perform dialysis using a hemodialysis catheter [
         <a href="#rid69">
          69
         </a>
         ]. While this option eliminates the impact of AV flow on PH, it is not suitable for long-term hemodialysis. (See
         <a class="medical medical_review" href="/z/d/html/115151.html" rel="external">
          "Approach to the adult patient needing vascular access for chronic hemodialysis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4171119840">
         <span class="h3">
          Patients on hemodialysis
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients receiving hemodialysis who have PH, we treat patients with aggressive volume management and address AV access issues that may be contributing to PH.
        </p>
        <p class="headingAnchor" id="H3915949179">
         <span class="h4">
          Volume management
         </span>
         <span class="headingEndMark">
          —
         </span>
         We manage patients with ESKD-PH who are on hemodialysis with aggressive removal of volume. We maintain the estimated dry weight as low as possible without causing intra- or interdialytic hypotension. This may require changes in the dialysis prescription to provide longer or more frequent dialysis sessions to safely achieve a lower dry weight (eg, daily sessions). (See
         <a class="medical medical_review" href="/z/d/html/1945.html" rel="external">
          "Intradialytic hypotension in an otherwise stable patient", section on 'Prevention of recurrent episodes'
         </a>
         .).
        </p>
        <p class="headingAnchor" id="H2149237049">
         <span class="h4">
          AV access management
         </span>
         <span class="headingEndMark">
          —
         </span>
         In general, for patients on hemodialysis, the arteriovenous (AV) access is managed according to the severity of symptoms and the level of flow through the AV access. (See
         <a class="medical medical_review" href="/z/d/html/15074.html" rel="external">
          "High-flow hemodialysis arteriovenous access", section on 'Access flow measurement'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Severe symptoms
         </strong>
         – For patients with severe symptoms (eg, New York Heart Association class III/IV  (
         <a class="graphic graphic_table graphicRef52683" href="/z/d/graphic/52683.html" rel="external">
          table 4
         </a>
         )), the AV access generally requires ligation regardless of the measured volume of flow. The patient should ideally be converted to peritoneal dialysis, if possible, or to hemodialysis using a tunneled hemodialysis catheter [
         <a href="#rid70">
          70
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15074.html" rel="external">
          "High-flow hemodialysis arteriovenous access", section on 'AV access ligation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mild to moderate symptoms
         </strong>
         – For patients with mild to moderate symptoms (eg, New York Heart Association class I to II) who have either high-flow AV access (ie, flow ≥1500 mL/min [
         <a href="#rid71">
          71-75
         </a>
         ])
         <strong>
          or
         </strong>
         moderate flow (800 to 1500 mL/min) and significant reduction in pulmonary pressures with AV access compression (see
         <a class="local">
          'Classification and assessment of arteriovenous access contribution'
         </a>
         above), we suggest a flow reduction procedure rather than observation. For all other patients with mild to moderate symptoms, AV access management is uncertain and should be individualized and agreed upon by experts and the patient. As an example, a flow reduction procedure may be considered in a patient with high flow and minimal or no response to manual compression, although outcomes are unknown in this subgroup. Alternatively, observation with a view to having a low threshold for flow reduction may also be appropriate (eg, patient with normal AV flow).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The goal of flow reduction procedures is to decrease flow to suggested levels of 800 mL/min for an AV fistula and 1000 mL/min for an AV graft in a patient with a normal blood pressure [
         <a href="#rid76">
          76,77
         </a>
         ]. To achieve effective hemodialysis while improving PH, the AV access flow should be reduced to levels no lower than 500 to 600 mL/min for AV fistulae and 600 to 700 mL/min for AV grafts. (See
         <a class="medical medical_review" href="/z/d/html/15074.html" rel="external">
          "High-flow hemodialysis arteriovenous access", section on 'Flow reduction'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/113760.html" rel="external">
          "Hemodialysis access-induced distal ischemia", section on 'Precision banding'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         After flow reduction, close patient follow-up to determine the course of the patient's symptoms (eg, dyspnea, edema) is important. Pulmonary pressures should decrease following either flow reduction or access ligation. However, the response is variable depending upon the etiology of PH. In cases with predominantly postcapillary PH, pulmonary pressures should fall as soon as cardiac pressures decrease. In those with predominantly precapillary PH, the response may be minimal, if any. Nevertheless, the beneficial effect of flow reduction on cardiac output should slow the rate of PH progression.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If symptoms improve, the patient should continue to be monitored. The interval for evaluation should be determined by the patient's individual situation. (See
         <a class="local">
          'Monitoring for PH'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If symptoms do not improve after flow reduction, we repeat echocardiography and right heart catheterization, and if symptoms are due to worsening PH, the access should be ligated. Peritoneal dialysis should be initiated, if feasible. If hemodialysis is to be continued, a tunneled hemodialysis catheter should be placed. (See
         <a class="local">
          'Patients on peritoneal dialysis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3337101755">
         <span class="h3">
          Patients on peritoneal dialysis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Similar to patients with ESKD-PH on hemodialysis, patients with ESKD-PH on peritoneal dialysis should be managed with aggressive removal of volume to maintain an estimated dry weight as low as possible without causing intra- or interdialytic hypotension. The issues with access blood flow that are relevant to patients on hemodialysis do not apply to those on peritoneal dialysis. (See
         <a class="local">
          'Volume management'
         </a>
         above.)
        </p>
        <p>
         For most patients with PH who are not suited to, decline, or fail PD, and in whom dialysis is needed long term, HD using a low-flow AV access (such as a radial-cephalic AV fistula) is an option. (See
         <a class="medical medical_review" href="/z/d/html/1858.html" rel="external">
          "Evaluating patients for chronic peritoneal dialysis and selection of modality", section on 'Available modalities'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1687019196">
         <span class="h2">
          Monitoring for PH
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pulmonary hypertension (PH) is progressive regardless of the chosen dialysis modality, access management, and supportive therapy for underlying disorders. Although there is no consensus, we clinically monitor all patients with ESKD-PH for worsening symptoms of PH at every dialysis treatment, particularly after creation of an AV access, initiation of dialysis, and following ligation or flow reduction procedures. (See
         <a class="medical medical_review" href="/z/d/html/8249.html" rel="external">
          "Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For those with known PH who have symptoms that do not improve or progress despite dialysis or aggressive ultrafiltration, we often repeat echocardiography and/or a right heart catheterization (RHC) and AV compression and flow studies to evaluate for progressive disease. (See
         <a class="local">
          'Initial diagnostic evaluation'
         </a>
         above and
         <a class="local">
          'Patients on hemodialysis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with preexisting PH who do not worsen after dialysis or AV access placement, we typically obtain periodic echocardiograms, the frequency of which is based upon clinical judgment (eg, every one to two years in stable patients or at one to two months after AV access creation) to reassess heart size, function, and pulmonary hemodynamics, although the value of this approach is unproven.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H99691878">
         <span class="h2">
          Refractory disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with persistent, severe PH (eg, severe symptoms and/or mean pulmonary arterial pressure [mPAP] greater than 35 mmHg) despite dialysis and AV fistula management should be referred to centers with expertise in the management of PH for possible evaluation in trials of PH-specific therapy [
         <a href="#rid8">
          8
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8250.html" rel="external">
          "Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy"
         </a>
         .)
        </p>
        <p>
         There is a paucity of data describing the impact of PH-specific therapy in ESKD-PH [
         <a href="#rid19">
          19,78
         </a>
         ]. One retrospective study of 18 patients on dialysis for ESKD, most of whom had scleroderma-associated PH (and kidney disease) or chronic thromboembolic PH (ie, group 1 and 4 PH  (
         <a class="graphic graphic_table graphicRef66348" href="/z/d/graphic/66348.html" rel="external">
          table 2
         </a>
         )), described successful treatment of PH with PH-specific therapy [
         <a href="#rid19">
          19
         </a>
         ]. Hypotension was common as an adverse effect.
        </p>
        <p class="headingAnchor" id="H102850402">
         <span class="h1">
          KIDNEY TRANSPLANTATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among patients with ESKD who are being evaluated for kidney transplantation, the presence of moderate to severe pulmonary hypertension may affect their transplant candidacy. Severe pulmonary hypertension has been associated with decreased posttransplant survival and, among recipients of a deceased-donor kidney, an increased risk of early kidney allograft dysfunction. Lowering the mean pulmonary artery pressure before transplant can be challenging and involves a combination of aggressive fluid management, fistula flow control, and in some cases, pulmonary arterial hypertension therapies, when indicated. These issues are discussed in more detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7309.html" rel="external">
          "Kidney transplantation in adults: Evaluation of the potential kidney transplant recipient", section on 'Pulmonary disease'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3868930531">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with ESKD, PH is an independent predictor of cardiovascular events and mortality [
         <a href="#rid2">
          2-5,79,80
         </a>
         ]. This is true for both patients with predialysis chronic kidney disease (CKD) and those on dialysis:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study of patients with CKD stage 3 through 5, a cardiovascular event occurred more frequently among patients with PH compared with those without PH (48 versus 21 percent, respectively) over a median of 22 months [
         <a href="#rid14">
          14
         </a>
         ]. The most common event was acute decompensated heart failure (25 percent), followed by stroke (20 percent) and cardiac arrest (12 percent). Higher mortality was also noted in patients with PH (29 versus 17 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study of patients on dialysis, those with PH had a higher mortality compared with those without PH (31 versus 4 percent) [
         <a href="#rid2">
          2
         </a>
         ]. Other observational studies have also reported similar findings [
         <a href="#rid6">
          6,45
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The impact of preexisting PH on allograft function after kidney transplant is unclear. In one retrospective study, pretransplant PH was associated with a higher rate of graft failure compared with patients without PH who underwent kidney transplant [
         <a href="#rid81">
          81
         </a>
         ]. In contrast, another retrospective study described no difference in allograft survival between those with or without PH [
         <a href="#rid82">
          82
         </a>
         ]. However, the varying definition and tests used to measure PH in this population may influence the accuracy of prognostic studies.
        </p>
        <p>
         Although rare, PH may predispose a patient to the development of a paradoxical embolus if a patent foramen ovale or atrial septal defect is present [
         <a href="#rid83">
          83
         </a>
         ]. There are several cases in the literature in which a devastating paradoxical embolus occurred after a thrombectomy of a dialysis access [
         <a href="#rid84">
          84-88
         </a>
         ]. The most frequent sites of paradoxical embolism are the extremities (50 percent) and the brain (40 percent), while the heart, spleen, and kidney are more rarely affected [
         <a href="#rid89">
          89
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1092.html" rel="external">
          "Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/112120.html" rel="external">
          "Embolism to the lower extremities"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2028289063">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/115503.html" rel="external">
          "Society guideline links: Pulmonary hypertension in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1042878597">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Overview
         </strong>
         – Patients with end-stage kidney disease (ESKD), particularly those on hemodialysis (HD), are at increased risk for development or worsening of pulmonary hypertension (PH). The increased risk is related in part to the arteriovenous (AV) access although other factors related to ESKD also contribute. (See
         <a class="local">
          'Incidence'
         </a>
         above and
         <a class="local">
          'Classification and pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
         – The symptoms and signs of PH in patients with ESKD are the same as in those without ESKD (eg, progressive dyspnea, fatigue, syncope, signs of right heart failure). Similar to PH associated with other etiologies, PH in patients with ESKD is progressive and may only be suspected when PH progresses in severity and right heart failure develops. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis and evaluation
         </strong>
         – Evaluation and diagnosis of PH in patients with ESKD are similar to those for patients without ESKD  (
         <a class="graphic graphic_algorithm graphicRef138556" href="/z/d/graphic/138556.html" rel="external">
          algorithm 1
         </a>
         ). We typically begin with transthoracic echocardiography, a search for common etiologies associated with PH, and the selective performance of right heart catheterization (RHC) to confirm or exclude PH. (See
         <a class="local">
          'Initial diagnostic evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – For patients with ESKD-related PH (ESKD-PH), we follow the same basic principles of management as for other patients with PH  (
         <a class="graphic graphic_algorithm graphicRef138519" href="/z/d/graphic/138519.html" rel="external">
          algorithm 2
         </a>
         ). Patients should be comanaged by clinicians who have expertise in ESKD as well as clinicians with expertise in PH.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          General measures
         </strong>
         – Patients with ESKD-PH should exercise as tolerated, receive routine vaccinations, be counselled against smoking and vaping, and maintain a normal body mass index. When indicated, they should also be treated with oxygen and diuretics (when feasible). We typically manage volume aggressively. We optimize therapies for any comorbidities known to be associated with or worsen PH, particularly heart failure, obstructive sleep apnea, and underlying lung disease. (See
         <a class="local">
          'General measures in all patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Patients not yet on dialysis
         </strong>
         – For patients with preexisting, symptomatic PH who are being considered for maintenance dialysis, we suggest peritoneal dialysis (PD) rather than HD as the choice of dialysis modality (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). PD obviates the need for AV access placement and provides daily ultrafiltration that may prevent interdialytic volume overload. For most patients who are not suited to, decline, or fail PD, we evaluate for HD using a low-flow AV access (eg, radial-cephalic AV fistula). (See
         <a class="local">
          'Patients on hemodialysis'
         </a>
         above and
         <a class="local">
          'Predialysis patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Patients already on dialysis
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Volume management
         </strong>
         – All patients on HD or PD with ESKD-PH should undergo aggressive removal of volume. We maintain the estimated dry weight as low as possible without causing intra- or interdialytic hypotension. (See
         <a class="local">
          'Volume management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          AV access management
         </strong>
         – For patients with ESKD-PH who have an AV access, we assess flow through the AV access (typically using Doppler ultrasonography) and also measure the potential contribution of flow through the AV access to pulmonary hemodynamics. Patients who have severe symptoms of PH generally require ligation of their AV access. For patients with mild-to-moderate symptoms (eg, New York Heart Association class I to II) who have either high-flow AV access (ie, flow ≥1500 mL/min )
         <strong>
          or
         </strong>
         moderate flow (800 to 1500 mL/min) and significant reduction in pulmonary pressures with AV access compression, we suggest a flow reduction procedure (eg, precision banding) rather than observation (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). In all others, therapy should be individualized. (See
         <a class="local">
          'AV access management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Refractory disease
         </strong>
         – Patients with persistent, severe PH (eg, severe symptoms and/or mean pulmonary arterial pressure greater than 35 mmHg) despite dialysis and AV fistula management should be referred to centers with expertise in the management of PH for possible evaluation in trials of PH-specific therapy. (See
         <a class="local">
          'Refractory disease'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Yigla M, Abassi Z, Reisner SA, Nakhoul F. Pulmonary hypertension in hemodialysis patients: an unrecognized threat. Semin Dial 2006; 19:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yigla M, Nakhoul F, Sabag A, et al. Pulmonary hypertension in patients with end-stage renal disease. Chest 2003; 123:1577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Acarturk G, Albayrak R, Melek M, et al. The relationship between arteriovenous fistula blood flow rate and pulmonary artery pressure in hemodialysis patients. Int Urol Nephrol 2008; 40:509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alkhouli M, Sandhu P, Boobes K, et al. Cardiac complications of arteriovenous fistulas in patients with end-stage renal disease. Nefrologia 2015; 35:234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Selvaraj S, Shah SJ, Ommerborn MJ, et al. Pulmonary Hypertension Is Associated With a Higher Risk of Heart Failure Hospitalization and Mortality in Patients With Chronic Kidney Disease: The Jackson Heart Study. Circ Heart Fail 2017; 10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reque J, Quiroga B, Ruiz C, et al. Pulmonary hypertension is an independent predictor of cardiovascular events and mortality in haemodialysis patients. Nephrology (Carlton) 2016; 21:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019; 53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bolignano D, Rastelli S, Agarwal R, et al. Pulmonary hypertension in CKD. Am J Kidney Dis 2013; 61:612.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kiykim AA, Horoz M, Ozcan T, et al. Pulmonary hypertension in hemodialysis patients without arteriovenous fistula: the effect of dialyzer composition. Ren Fail 2010; 32:1148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Havlucu Y, Kursat S, Ekmekci C, et al. Pulmonary hypertension in patients with chronic renal failure. Respiration 2007; 74:503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Unal A, Sipahioglu M, Oguz F, et al. Pulmonary hypertension in peritoneal dialysis patients: prevalence and risk factors. Perit Dial Int 2009; 29:191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Etemadi J, Zolfaghari H, Firoozi R, et al. Unexplained pulmonary hypertension in peritoneal dialysis and hemodialysis patients. Rev Port Pneumol 2012; 18:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fabbian F, Cantelli S, Molino C, et al. Pulmonary hypertension in dialysis patients: a cross-sectional italian study. Int J Nephrol 2010; 2011:283475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reque J, Garcia-Prieto A, Linares T, et al. Pulmonary Hypertension Is Associated with Mortality and Cardiovascular Events in Chronic Kidney Disease Patients. Am J Nephrol 2017; 45:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Issa N, Krowka MJ, Griffin MD, et al. Pulmonary hypertension is associated with reduced patient survival after kidney transplantation. Transplantation 2008; 86:1384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pabst S, Hammerstingl C, Hundt F, et al. Pulmonary hypertension in patients with chronic kidney disease on dialysis and without dialysis: results of the PEPPER-study. PLoS One 2012; 7:e35310.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC), European Respiratory Society (ERS), International Society of Heart and Lung Transplantation (ISHLT), et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34:1219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173:1023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arevalo C, White RJ, Le T, Lachant D. Vasodilator use in precapillary pulmonary hypertension with end stage kidney disease: A single center experience. Respir Med 2021; 188:106596.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martínez-Gallardo R, Ferreira-Morong F, García-Pino G, et al. Congestive heart failure in patients with advanced chronic kidney disease: association with pre-emptive vascular access placement. Nefrologia 2012; 32:206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheung AK, Sarnak MJ, Yan G, et al. Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. Kidney Int 2004; 65:2380.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stack AG, Bloembergen WE. A cross-sectional study of the prevalence and clinical correlates of congestive heart failure among incident US dialysis patients. Am J Kidney Dis 2001; 38:992.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yigla M, Dabbah S, Azzam ZS, et al. Background diseases in 671 patients with moderate to severe pulmonary hypertension. Isr Med Assoc J 2000; 2:684.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Edmonston DL, Parikh KS, Rajagopal S, et al. Pulmonary Hypertension Subtypes and Mortality in CKD. Am J Kidney Dis 2020; 75:713.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Leary JM, Assad TR, Xu M, et al. Pulmonary hypertension in patients with chronic kidney disease: invasive hemodynamic etiology and outcomes. Pulm Circ 2017; 7:674.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gündüz OH, Fertig N, Lucas M, Medsger TA Jr. Systemic sclerosis with renal crisis and pulmonary hypertension: a report of eleven cases. Arthritis Rheum 2001; 44:1663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Terzano C, Conti V, Di Stefano F, et al. Comorbidity, hospitalization, and mortality in COPD: results from a longitudinal study. Lung 2010; 188:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong HS, Williams AJ, Mok Y. The relationship between pulmonary hypertension and obstructive sleep apnea. Curr Opin Pulm Med 2017; 23:517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kraus MA, Hamburger RJ. Sleep apnea in renal failure. Adv Perit Dial 1997; 13:88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Young T, Palta M, Dempsey J, et al. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993; 328:1230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roumelioti ME, Buysse DJ, Sanders MH, et al. Sleep-disordered breathing and excessive daytime sleepiness in chronic kidney disease and hemodialysis. Clin J Am Soc Nephrol 2011; 6:986.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pressman MR, Benz RL, Schleifer CR, Peterson DD. Sleep disordered breathing in ESRD: acute beneficial effects of treatment with nasal continuous positive airway pressure. Kidney Int 1993; 43:1134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yayan J, Rasche K, Vlachou A. Obstructive Sleep Apnea and Chronic Kidney Disease. Adv Exp Med Biol 2017; 1022:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sakaguchi Y, Shoji T, Kawabata H, et al. High prevalence of obstructive sleep apnea and its association with renal function among nondialysis chronic kidney disease patients in Japan: a cross-sectional study. Clin J Am Soc Nephrol 2011; 6:995.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zoccali C, Mallamaci F, Tripepi G. Nocturnal hypoxemia predicts incident cardiovascular complications in dialysis patients. J Am Soc Nephrol 2002; 13:729.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kumar G, Sakhuja A, Taneja A, et al. Pulmonary embolism in patients with CKD and ESRD. Clin J Am Soc Nephrol 2012; 7:1584.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harp RJ, Stavropoulos SW, Wasserstein AG, Clark TW. Pulmonary hypertension among end-stage renal failure patients following hemodialysis access thrombectomy. Cardiovasc Intervent Radiol 2005; 28:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hsieh MY, Lin L, Chen TY, et al. Pulmonary Hypertension in Hemodialysis Patients Following Repeated Endovascular Thrombectomy. Acta Cardiol Sin 2016; 32:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smits HF, Van Rijk PP, Van Isselt JW, et al. Pulmonary embolism after thrombolysis of hemodialysis grafts. J Am Soc Nephrol 1997; 8:1458.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abassi Z, Nakhoul F, Khankin E, et al. Pulmonary hypertension in chronic dialysis patients with arteriovenous fistula: pathogenesis and therapeutic prospective. Curr Opin Nephrol Hypertens 2006; 15:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakhoul F, Yigla M, Gilman R, et al. The pathogenesis of pulmonary hypertension in haemodialysis patients via arterio-venous access. Nephrol Dial Transplant 2005; 20:1686.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chuang MK, Chang CH, Chan CY. The Effect of Haemodialysis Access Types on Cardiac Performance and Morbidities in Patients with Symptomatic Heart Disease. PLoS One 2016; 11:e0148278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Basile C, Lomonte C, Vernaglione L, et al. The relationship between the flow of arteriovenous fistula and cardiac output in haemodialysis patients. Nephrol Dial Transplant 2008; 23:282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al-Qadi M, LeVarge B, Ford HJ. Epidemiology, Pathogenesis, and Clinical Approach in Group 5 Pulmonary Hypertension. Front Med (Lausanne) 2020; 7:616720.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agarwal R. Prevalence, determinants and prognosis of pulmonary hypertension among hemodialysis patients. Nephrol Dial Transplant 2012; 27:3908.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramasubbu K, Deswal A, Herdejurgen C, et al. A prospective echocardiographic evaluation of pulmonary hypertension in chronic hemodialysis patients in the United States: prevalence and clinical significance. Int J Gen Med 2010; 3:279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abedini M, Sadeghi M, Naini AE, et al. Pulmonary hypertension among patients on dialysis and kidney transplant recipients. Ren Fail 2013; 35:560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clarkson MR, Giblin L, Brown A, et al. Reversal of pulmonary hypertension after ligation of a brachiocephalic arteriovenous fistula. Am J Kidney Dis 2002; 40:E8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fabbian F. [Should pulmonary artery pressure be evaluated in uremic patients?]. G Ital Nefrol 2011; 28:356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sise ME, Courtwright AM, Channick RN. Pulmonary hypertension in patients with chronic and end-stage kidney disease. Kidney Int 2013; 84:682.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Casas-Aparicio G, Castillo-Martínez L, Orea-Tejeda A, et al. The effect of successful kidney transplantation on ventricular dysfunction and pulmonary hypertension. Transplant Proc 2010; 42:3524.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giaid A. Nitric oxide and endothelin-1 in pulmonary hypertension. Chest 1998; 114:208S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zoccali C. The endothelium as a target in renal diseases. J Nephrol 2007; 20 Suppl 12:S39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wever R, Boer P, Hijmering M, et al. Nitric oxide production is reduced in patients with chronic renal failure. Arterioscler Thromb Vasc Biol 1999; 19:1168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morris ST, Jardine AG. The vascular endothelium in chronic renal failure. J Nephrol 2000; 13:96.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vaziri ND. Effect of chronic renal failure on nitric oxide metabolism. Am J Kidney Dis 2001; 38:S74.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amin M, Fawzy A, Hamid MA, Elhendy A. Pulmonary hypertension in patients with chronic renal failure: role of parathyroid hormone and pulmonary artery calcifications. Chest 2003; 124:2093.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schepers E, Glorieux G, Dou L, et al. Guanidino compounds as cause of cardiovascular damage in chronic kidney disease: an in vitro evaluation. Blood Purif 2010; 30:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shi B, Ni Z, Zhou W, et al. Circulating levels of asymmetric dimethylarginine are an independent risk factor for left ventricular hypertrophy and predict cardiovascular events in pre-dialysis patients with chronic kidney disease. Eur J Intern Med 2010; 21:444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aldámiz-Echevarría L, Andrade F. Asymmetric dimethylarginine, endothelial dysfunction and renal disease. Int J Mol Sci 2012; 13:11288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilcken DE, Sim AS, Wang J, Wang XL. Asymmetric dimethylarginine (ADMA) in vascular, renal and hepatic disease and the regulatory role of L-arginine on its metabolism. Mol Genet Metab 2007; 91:309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zoccali C, Bode-Böger S, Mallamaci F, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358:2113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kielstein JT, Böger RH, Bode-Böger SM, et al. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 2002; 13:170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thakkar V, Stevens W, Prior D, et al. The role of asymmetric dimethylarginine alone and in combination with N-terminal pro-B-type natriuretic peptide as a screening biomarker for systemic sclerosis-related pulmonary arterial hypertension: a case control study. Clin Exp Rheumatol 2016; 34 Suppl 100:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iwashima Y, Horio T, Takami Y, et al. Effects of the creation of arteriovenous fistula for hemodialysis on cardiac function and natriuretic peptide levels in CRF. Am J Kidney Dis 2002; 40:974.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nitta K, Akiba T, Uchida K, et al. The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. Am J Kidney Dis 2003; 42:303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 2015; 46:903.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yigla M, Keidar Z, Safadi I, et al. Pulmonary calcification in hemodialysis patients: correlation with pulmonary artery pressure values. Kidney Int 2004; 66:806.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Germain MJ, Cohen LM. Maintaining quality of life at the end of life in the end-stage renal disease population. Adv Chronic Kidney Dis 2008; 15:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wasse H, Singapuri MS. High-output heart failure: how to define it, when to treat it, and how to treat it. Semin Nephrol 2012; 32:551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malik J, Kudlicka J, Tesar V, Linhart A. Cardiac safety in vascular access surgery and maintenance. Contrib Nephrol 2015; 184:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malík J, Tuka V, Mokrejšová M, et al. Mechanisms of chronic heart failure development in end-stage renal disease patients on chronic hemodialysis. Physiol Res 2009; 58:613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beathard GA, Jennings WC, Wasse H, et al. ASDIN white paper: Management of cephalic arch stenosis endorsed by the American Society of Diagnostic and Interventional Nephrology. J Vasc Access 2023; 24:358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beathard GA, Jennings WC, Wasse H, et al. ASDIN white paper: Assessment and management of hemodialysis access-induced distal ischemia by interventional nephrologists. J Vasc Access 2020; 21:543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kanno T, Kanno Y, Shiroi K, et al. Features of high flow access in the elderly. J Vasc Access 2019; 20:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beathard GA, Lok CE, Glickman MH, et al. Definitions and End Points for Interventional Studies for Arteriovenous Dialysis Access. Clin J Am Soc Nephrol 2018; 13:501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beathard GA, Spergel LM. Hand ischemia associated with dialysis vascular access: an individualized access flow-based approach to therapy. Semin Dial 2013; 26:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nishimura M, Tokoro T, Yamazaki S, et al. Idiopathic pre-capillary pulmonary hypertension in patients with end-stage kidney disease: effect of endothelin receptor antagonists. Clin Exp Nephrol 2017; 21:1088.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abdelwhab S, Elshinnawy S. Pulmonary hypertension in chronic renal failure patients. Am J Nephrol 2008; 28:990.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yigla M, Fruchter O, Aharonson D, et al. Pulmonary hypertension is an independent predictor of mortality in hemodialysis patients. Kidney Int 2009; 75:969.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zlotnick DM, Axelrod DA, Chobanian MC, et al. Non-invasive detection of pulmonary hypertension prior to renal transplantation is a predictor of increased risk for early graft dysfunction. Nephrol Dial Transplant 2010; 25:3090.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sadat B, Tirunagari D, Karthikeyan V, et al. Clinical impact of pre-kidney transplant pulmonary hypertension on post-transplant outcomes. Int J Cardiovasc Imaging 2021; 37:1979.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu S, Ahmad I, Qayyum S, et al. Paradoxical embolism after declotting of hemodialysis fistulae/grafts in patients with patent foramen ovale. Clin J Am Soc Nephrol 2011; 6:1333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bentaarit B, Duval AM, Maraval A, et al. Paradoxical embolism following thromboaspiration of an arteriovenous fistula thrombosis: a case report. J Med Case Rep 2010; 4:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Briefel GR, Regan F, Petronis JD. Cerebral embolism after mechanical thrombolysis of a clotted hemodialysis access. Am J Kidney Dis 1999; 34:341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santos JP, Hamadeh Z, Ansari N. Cerebrovascular accident secondary to paradoxical embolism following arteriovenous graft thrombectomy. Case Rep Nephrol 2012; 2012:183730.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Owens CA, Yaghmai B, Aletich V, et al. Fatal paradoxic embolism during percutaneous thrombolysis of a hemodialysis graft. AJR Am J Roentgenol 1998; 170:742.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pinard EA, Fazal S, Schussler JM. Catastrophic paradoxical embolus after hemodialysis access thrombectomy in a patient with a patent foramen ovale. Int Urol Nephrol 2013; 45:1215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gill TJ, Campbell CC. Radial artery occlusion by a paradoxical embolism: a case report. J Hand Surg Am 1995; 20:406.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 112442 Version 20.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16970730" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Pulmonary hypertension in hemodialysis patients: an unrecognized threat.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12740276" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Pulmonary hypertension in patients with end-stage renal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17985208" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : The relationship between arteriovenous fistula blood flow rate and pulmonary artery pressure in hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26299166" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Cardiac complications of arteriovenous fistulas in patients with end-stage renal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28611127" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Pulmonary Hypertension Is Associated With a Higher Risk of Heart Failure Hospitalization and Mortality in Patients With Chronic Kidney Disease: The Jackson Heart Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26369737" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Pulmonary hypertension is an independent predictor of cardiovascular events and mortality in haemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30545968" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Haemodynamic definitions and updated clinical classification of pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23164943" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Pulmonary hypertension in CKD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20954973" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Pulmonary hypertension in hemodialysis patients without arteriovenous fistula: the effect of dialyzer composition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17505128" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Pulmonary hypertension in patients with chronic renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19293357" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Pulmonary hypertension in peritoneal dialysis patients: prevalence and risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21920698" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Unexplained pulmonary hypertension in peritoneal dialysis and hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21151534" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Pulmonary hypertension in dialysis patients: a cross-sectional italian study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27941345" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Pulmonary Hypertension Is Associated with Mortality and Cardiovascular Events in Chronic Kidney Disease Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19034007" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Pulmonary hypertension is associated with reduced patient survival after kidney transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22530005" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Pulmonary hypertension in patients with chronic kidney disease on dialysis and without dialysis: results of the PEPPER-study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19749199" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Guidelines for the diagnosis and treatment of pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16456139" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Pulmonary arterial hypertension in France: results from a national registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34509135" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Vasodilator use in precapillary pulmonary hypertension with end stage kidney disease: A single center experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22425802" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Congestive heart failure in patients with advanced chronic kidney disease: association with pre-emptive vascular access placement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15149351" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11684552" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : A cross-sectional study of the prevalence and clinical correlates of congestive heart failure among incident US dialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11062769" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Background diseases in 671 patients with moderate to severe pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31732231" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Pulmonary Hypertension Subtypes and Mortality in CKD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28660793" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Pulmonary hypertension in patients with chronic kidney disease: invasive hemodynamic etiology and outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11465718" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Systemic sclerosis with renal crisis and pulmonary hypertension: a report of eleven cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20066539" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Comorbidity, hospitalization, and mortality in COPD: results from a longitudinal study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28786883" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : The relationship between pulmonary hypertension and obstructive sleep apnea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9360657" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Sleep apnea in renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8464434" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : The occurrence of sleep-disordered breathing among middle-aged adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21441128" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Sleep-disordered breathing and excessive daytime sleepiness in chronic kidney disease and hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8510393" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Sleep disordered breathing in ESRD: acute beneficial effects of treatment with nasal continuous positive airway pressure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28567615" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Obstructive Sleep Apnea and Chronic Kidney Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21415314" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : High prevalence of obstructive sleep apnea and its association with renal function among nondialysis chronic kidney disease patients in Japan: a cross-sectional study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11856778" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Nocturnal hypoxemia predicts incident cardiovascular complications in dialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22837271" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Pulmonary embolism in patients with CKD and ESRD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15772721" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Pulmonary hypertension among end-stage renal failure patients following hemodialysis access thrombectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27274170" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Pulmonary Hypertension in Hemodialysis Patients Following Repeated Endovascular Thrombectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9294839" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Pulmonary embolism after thrombolysis of hemodialysis grafts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16775448" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Pulmonary hypertension in chronic dialysis patients with arteriovenous fistula: pathogenesis and therapeutic prospective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15840664" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : The pathogenesis of pulmonary hypertension in haemodialysis patients via arterio-venous access.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26848850" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : The Effect of Haemodialysis Access Types on Cardiac Performance and Morbidities in Patients with Symptomatic Heart Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17942475" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : The relationship between the flow of arteriovenous fistula and cardiac output in haemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33842491" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Epidemiology, Pathogenesis, and Clinical Approach in Group 5 Pulmonary Hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22290987" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Prevalence, determinants and prognosis of pulmonary hypertension among hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21042428" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : A prospective echocardiographic evaluation of pulmonary hypertension in chronic hemodialysis patients in the United States: prevalence and clinical significance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23438072" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Pulmonary hypertension among patients on dialysis and kidney transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12200825" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Reversal of pulmonary hypertension after ligation of a brachiocephalic arteriovenous fistula.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21809302" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : [Should pulmonary artery pressure be evaluated in uremic patients?].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23739239" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Pulmonary hypertension in patients with chronic and end-stage kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21094809" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : The effect of successful kidney transplantation on ventricular dysfunction and pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9741571" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Nitric oxide and endothelin-1 in pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18050141" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : The endothelium as a target in renal diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10323766" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Nitric oxide production is reduced in patients with chronic renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10858970" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : The vascular endothelium in chronic renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11576927" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Effect of chronic renal failure on nitric oxide metabolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14665485" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Pulmonary hypertension in patients with chronic renal failure: role of parathyroid hormone and pulmonary artery calcifications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21079396" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Guanidino compounds as cause of cardiovascular damage in chronic kidney disease: an in vitro evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20816602" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Circulating levels of asymmetric dimethylarginine are an independent risk factor for left ventricular hypertrophy and predict cardiovascular events in pre-dialysis patients with chronic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23109853" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Asymmetric dimethylarginine, endothelial dysfunction and renal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17560156" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Asymmetric dimethylarginine (ADMA) in vascular, renal and hepatic disease and the regulatory role of L-arginine on its metabolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11784625" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11752034" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27214686" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : The role of asymmetric dimethylarginine alone and in combination with N-terminal pro-B-type natriuretic peptide as a screening biomarker for systemic sclerosis-related pulmonary arterial hypertension: a case control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12407642" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Effects of the creation of arteriovenous fistula for hemodialysis on cardiac function and natriuretic peptide levels in CRF.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12900812" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26318161" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15253737" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Pulmonary calcification in hemodialysis patients: correlation with pulmonary artery pressure values.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18334237" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Maintaining quality of life at the end of life in the end-stage renal disease population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23217335" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : High-output heart failure: how to define it, when to treat it, and how to treat it.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25676293" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Cardiac safety in vascular access surgery and maintenance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19093713" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Mechanisms of chronic heart failure development in end-stage renal disease patients on chronic hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34392712" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : ASDIN white paper: Management of cephalic arch stenosis endorsed by the American Society of Diagnostic and Interventional Nephrology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31884872" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : ASDIN white paper: Assessment and management of hemodialysis access-induced distal ischemia by interventional nephrologists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31032728" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Features of high flow access in the elderly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28729383" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Definitions and End Points for Interventional Studies for Arteriovenous Dialysis Access.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23581731" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Hand ischemia associated with dialysis vascular access: an individualized access flow-based approach to therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27757709" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Idiopathic pre-capillary pulmonary hypertension in patients with end-stage kidney disease: effect of endothelin receptor antagonists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18635926" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Pulmonary hypertension in chronic renal failure patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19212417" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Pulmonary hypertension is an independent predictor of mortality in hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20299337" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Non-invasive detection of pulmonary hypertension prior to renal transplantation is a predictor of increased risk for early graft dysfunction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33616784" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Clinical impact of pre-kidney transplant pulmonary hypertension on post-transplant outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21551024" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Paradoxical embolism after declotting of hemodialysis fistulae/grafts in patients with patent foramen ovale.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21029407" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Paradoxical embolism following thromboaspiration of an arteriovenous fistula thrombosis: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10430984" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Cerebral embolism after mechanical thrombolysis of a clotted hemodialysis access.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24533201" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Cerebrovascular accident secondary to paradoxical embolism following arteriovenous graft thrombectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9490966" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Fatal paradoxic embolism during percutaneous thrombolysis of a hemodialysis graft.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22367171" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Catastrophic paradoxical embolus after hemodialysis access thrombectomy in a patient with a patent foramen ovale.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7642916" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Radial artery occlusion by a paradoxical embolism: a case report.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
